Protagonist Therapeutics Inc. Welcome to Protagonist, a clinical-stage biopharmaceutical company We strive to improve patients’ lives through the power of peptide drug discovery and development, targeting areas of unmet need across rare and prevalent diseases where treatments are limited or inadequate
Protagonist Therapeutics Executives Quietly Cash In on Major Insider . . . Insider activity at Protagonist Therapeutics has been heating up, with several top executives recently cashing in significant amounts of company stock Director Harold Selick sold 24,000 shares for a total of $2,520,000 Chief Medical Officer Arturo MD Molina disposed of 15,000 shares in a sale valued at $1,571,850
Takeda grabs late-stage haematology drug from Protagonist Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics
FDA Approves Protagonist’s ICOTYDE: The Oral Peptide Revolution Hits . . . For Protagonist Therapeutics (Nasdaq: PTGX), the approval validates their peptide technology platform and provides a steady stream of royalty revenue that could fund their independent pipeline for years to come Conversely, the approval puts immediate pressure on Bristol Myers Squibb (NYSE: BMY) and their oral TYK2 inhibitor, Sotyktu
FDA approves J J, Protagonists blockbuster-to-be psoriasis pill Johnson Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the lucrative psoriasis market with a new approval for a much-anticipate
PROTAGONIST THERAPEUTICS, INC. _December 31, 2024 Second generation allosteric TYK2 inhibitors from Nimbus Therapeutics (recently in-licensed by Takeda) are moving into Phase 3 development, and a molecule from Ventyx Biosciences has initiated Phase 2 development Several small molecules that inhibit IL-17 have completed Phase 1 development